Download free PDF

Breast Biopsy Devices Market Size & Share 2023 to 2032

Market Size by Product (Needle Based Breast Biopsy Guns, Breast Biopsy Guidance Systems, Needle, & Forceps), Technique (Image Guided Biopsy, Liquid Biopsy).

Report ID: GMI7441
   |
Published Date: November 2023
 | 
Report Format: PDF

Download Free PDF

Breast Biopsy Devices Market Size

Breast Biopsy Devices Market size was valued at USD 1.8 billion in 2022 and is anticipated to register a CAGR of over 6.8% between 2023 and 2032. These devices are medical instruments or tools used by healthcare professionals to obtain tissue samples from the breast for diagnostic purposes. For instance, a report in the Journal of Clinical Oncology projects a 31% rise in new global female breast cancer cases, from 2,260,127 in 2020 to an estimated 2,964,197 cases in 2040.

Breast Biopsy Devices Market Key Takeaways

Market Size & Growth

  • 2022 Market Size: USD 1.8 Billion
  • 2032 Forecast Market Size: USD 3.6 Billion
  • CAGR (2023–2032): 6.8%

Key Market Drivers

  • Increasing incidence of breast cancer.
  • Technological advancements in breast biopsy equipment.
  • Rising awareness regarding breast cancer screening.
  • Favourable reimbursement scenario.

Challenges

  • High cost associated with breast biopsy procedure.
  • Risk of infection associated with the use of biopsy needles.

Furthermore, an improved reimbursement landscape for breast biopsy procedures and associated diagnostic tests incentivizes healthcare providers and patients to utilize these services.

COVID-19 Impact

The COVID-19 storm had cast a shadow over the market, disrupting healthcare services, triggering safety apprehensions among patients, leading to supply chain hiccups, constraining healthcare budgets, and diverting resources to the COVID-19 research front.
 

Breast Biopsy Devices Market

Breast Biopsy Devices Market Trends

Continuous advancements in biopsy technologies and equipment, such as more precise and minimally invasive techniques, improved imaging capabilities, and enhanced tissue sampling methods. For instance, Mammotome's Mammotome Elite Tetherless Biopsy System uses dual vacuum-assisted technology for precise breast biopsies and features an ergonomic design with multiple buttons for flexibility, enhancing efficiency in complex procedures.
 

  • Furthermore, public awareness campaigns and initiatives aimed at educating individuals about the importance of regular breast cancer screening and early detection have increased the demand for breast biopsy devices.
     
  • Therefore, this heightened awareness encourages more people to undergo screening, leading to higher utilization of biopsy devices, which is estimated to reach USD 4.8 billion by 2032.
     

Breast Biopsy Devices Market Analysis

Breast Biopsy Devices Market Size, By Product, 2021 - 2032 (USD Billion)

The market by product is categorized into breast biopsy guidance systems, needle-based breast biopsy guns, breast biopsy needles, breast biopsy forceps and other products. The needle-based breast biopsy guns segment is bifurcated into vacuum-assisted biopsy (VAB) devices, fine needle aspiration biopsy (FNAB) devices, and core needle biopsy (CNB) devices. This segment garnered USD 568 million revenue size in the year 2022 and is projected to have the fastest-growing CAGR in the forecast period.
 

  • Their ease of use, accurate lesion targeting, and compatibility with imaging guidance contribute to widespread adoption. Furthermore, advances in needle design and technology bolster diagnostic accuracy, instilling confidence among healthcare professionals.
     
Breast Biopsy Devices Market Revenue Share, By Technique, (2022)

Based on technique, the breast biopsy devices market is segmented into image guided biopsy and liquid biopsy. The image guided biopsy segment is further bifurcated into MRI guided breast biopsy, ultrasound guided breast biopsy, mammography guided stereotactic biopsy and other image guided biopsies. This segment garnered USD 1.3 billion revenue size in the year 2022.
 

  • Image-guided biopsy dominates due to its superior precision, offering real-time visualization through techniques such as ultrasound or stereotactic guidance. This precision enhances diagnostic outcomes, instilling confidence in healthcare professionals.
     
  • Furthermore, the technique's minimally invasive nature reduces patient discomfort, ensuring quicker recovery and driving widespread adoption.
     

Based on end-use, the breast biopsy devices market is segmented into hospitals and ambulatory surgical centres. The hospitals segment garnered USD 1.1 billion revenue size in the year 2022.
 

  • Hospitals dominates the segment, leveraging advanced infrastructure and skilled professionals to integrate sophisticated biopsy procedures seamlessly. Their possession of cutting-edge imaging technologies fosters widespread adoption. Moreover, patient trust in hospital-based diagnostic services contributes to a preference for breast biopsy procedures in these settings.
     
U.S. Breast Biopsy Devices Market Size, 2020- 2032 (USD Million)

U.S. breast biopsy devices market accounted for USD 649 million revenue size in 2022.
 

  • The U.S. has taken a commanding position in the industry, primarily due to its advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and proactive breast cancer awareness programs.
     
  • Furthermore, the country's robust reimbursement framework accelerates device adoption. For instance, in 2023, the American Cancer Society estimates 297,790 new cases of invasive breast cancer in the U.S., with an anticipated 43,700 women succumbing to the disease.
     

Breast Biopsy Devices Market Share

The breast biopsy devices industry is consolidated, with key players including, Medtronic plc, Hologic Inc, and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in January 2021, Hologic, Inc., acquired SOMATEX Medical Technologies GmbH, thereby strengthening its breast marker portfolio and consolidating its position in biopsy site markers and localization technologies. The strategic move also extended Hologic's sales presence in Europe by expanding its direct channel in Germany and augmenting its network of regional and international distributor partners.
 

Some of the eminent market participants operating in the breast biopsy devices industry include:

  • Stryker Corporation
  • Boston Scientific Corporation
  • FUJIFILM Holdings Corporation
  • Argon Medical Devices, Inc
  • Hologic Inc
  • Cook Group Incorporated
  • Becton, Dickinson and Company (BD)
  • Medtronic plc
  • Olympus Corporation
  • Cardinal Health
  • INRAD Inc
  • Danaher Corporation
  • B. Braun Melsungen AGS
     

Breast Biopsy Devices Industry News:

  • In May 2023, Argon Medical Devices, a leader in device solutions for various medical fields, launched the SuperCore Advantage Semi-Automatic Biopsy Instrument in the U.S., expanding its soft tissue biopsy product line. This strategic introduction aimed to diversify the company's offering and enhance revenue.
     
  • In August 2022, Mammotome (Danaher Corporation) launched the Mammotome Revolve EX, the first vacuum-assisted biopsy system designed for the efficient excision of benign breast lesions, featuring double the speed compared to traditional systems. This product launch expanded the company's product portfolio, delivering a significant competitive edge.
     

Breast biopsy devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD and volume in Units from 2018 to 2032 for the following segments:

By Product, 2018 – 2032 (USD Million and Units)

  • Breast biopsy guidance systems 
    • Manual
    • Robotic
  • Needle based breast biopsy guns 
    • Vacuum-assisted biopsy (VAB) devices
    • Fine needle aspiration biopsy (FNAB) devices
    • Core needle biopsy (CNB) devices
  • Breast biopsy needles 
    • Disposable
    • Reusable
  • Breast biopsy forceps 
    • General biopsy forceps
    • Hot biopsy forceps
  • Other products 
    • Brushes
    • Curettes
    • Punches

By Technique, 2018 – 2032 (USD Million)

  • Image guided biopsy 
    • MRI guided breast biopsy
    • Ultrasound guided breast biopsy
    • Mammography guided stereotactic biopsy
    • Other image guided biopsies
  • Liquid Biopsy 
    • NGS based biopsy
    • PCR based biopsy
    • Micro-array based biopsy

By End-use, 2018 – 2032 (USD Million)

  • Hospitals
  • Ambulatory surgical centers
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East & Africa

 

Authors:  Mariam Faizullabhoy, Gauri Wani

Research methodology, data sources & validation process

This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.

Our 6-step research process

  1. 1. Research design & analyst oversight

    At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.

    Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.

  2. 2. Primary research

    Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.

  3. 3. Data mining & market analysis

    Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.

  4. 4. Market sizing

    Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.

  5. 5. Forecast model & key assumptions

    Every forecast includes explicit documentation of:

    • ✓ Key growth drivers and their assumed impact

    • ✓ Restraining factors and mitigation scenarios

    • ✓ Regulatory assumptions and policy change risk

    • ✓ Technology adoption curve parameter

    • ✓ Macroeconomic assumptions (GDP growth, inflation, currency)

    • ✓ Competitive dynamics and market entry/exit expectations

  6. 6. Validation & quality assurance

    The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.

    Our triple-layer validation process ensures maximum data reliability:

    • ✓ Statistical Validation

    • ✓ Expert Validation

    • ✓ Market Reality Check

Trust & credibility

10+
Years in Service
Consistent delivery since establishment
A+
BBB Accreditation
Professional standards & satisfaction
ISO
Certified Quality
ISO 9001-2015 Certified Company
150+
Research Analysts
Across 10+ industry verticals
95%
Client Retention
5-year relationship value

Verified data sources

  • Trade publications

    Security & defense sector journals and trade press

  • Industry databases

    Proprietary and third-party market databases

  • Regulatory filings

    Government procurement records and policy documents

  • Academic research

    University studies and specialist institution reports

  • Company reports

    Annual reports, investor presentations, and filings

  • Expert interviews

    C-suite, procurement leads, and technical specialists

  • GMI archive

    13,000+ published studies across 30+ industry verticals

  • Trade data

    Import/export volumes, HS codes, and customs records

Parameters studied & evaluated

Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →

Frequently Asked Question(FAQ) :
How big is the global breast biopsy devices market?
The global breast biopsy devices market was valued at USD 1.8 billion in 2022 and is estimated to reach USD 3.6 billion by 2032, backed by surge in breast cancer cases, favorable reimbursement policies, awareness about benefits of early detection.
How are hospitals influencing the demand for breast biopsy devices?
The hospitals segment generated USD 1.1 billion in 2022 and will continue to drive demand as these healthcare settings leverage advanced infrastructure and skilled professionals to integrate sophisticated biopsy procedures seamlessly, gaining patient
What is the size of the U.S. breast biopsy devices industry?
U.S. market accounted for USD 649 million in 2022 and is predicted to witness substantial growth through 2032, primarily due to the advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and proactive breast cancer awareness programs.
Which companies define the competitive landscape of breast biopsy devices market?
Stryker Corporation, Boston Scientific Corporation, FUJIFILM Holdings Corporation, Argon Medical Devices, Inc, Hologic Inc, Cook Group Incorporated, Becton, Dickinson and Company (BD), Medtronic plc, Olympus Corporation, Cardinal Health, and INRAD Inc among others.
Breast Biopsy Devices Market Scope
  • Breast Biopsy Devices Market Size

  • Breast Biopsy Devices Market Trends

  • Breast Biopsy Devices Market Analysis

  • Breast Biopsy Devices Market Share

Authors:  Mariam Faizullabhoy, Gauri Wani
Explore Our Licensing Options:

Starting at: $2,450

Premium Report Details:

Base Year: 2022

Companies Profiled: 12

Tables & Figures: 836

Countries Covered: 22

Pages: 679

Download Free PDF

We use cookies to enhance user experience. (Privacy Policy)